Recommended Pages at hemonctoday.com
Physicians with healthy habits likely to urge lifestyle changes to patients | HemOncToday
hemonctoday.com — “Physicians who practice healthy habits are likely to recommend important lifestyle modifications to their patients, results of a survey suggest.” View full resource at hemonctoday.com
Most Recently Shared on March 23, 2012 at 12:44 pm By:
Physicians with healthy habits likely to urge lifestyle changes to patients: http://t.co/wukIi0ny
ODAC rejects ridaforolimus as maintenance therapy for sarcoma | HemOncToday
hemonctoday.com — “An FDA panel rejected ridaforolimus as a maintenance therapy for patients with soft-tissue or bone ” View full resource at hemonctoday.com
Most Recently Shared on March 21, 2012 at 5:10 pm By:
ODAC rejects ridaforolimus as maintenance therapy for sarcoma: http://t.co/wgR3AMi1
ODAC supports approval of sarcoma drug | HemOncToday
hemonctoday.com — “An FDA panel overwhelmingly expressed its support for the approval of pazopanib for patients with advanced soft tissue ” View full resource at hemonctoday.com
Most Recently Shared on March 20, 2012 at 7:59 pm By:
Diesel exhaust exposure linked to increased risk for lung cancer mortality | HemOncToday
hemonctoday.com — “Diesel exhaust exposure linked to increased risk for lung cancer mortality | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on March 20, 2012 at 11:45 am By:
Diesel exhaust exposure linked to increased risk for lung cancer mortality: http://t.co/PZbII5oS
AAP now recommends HPV vaccine for boys and girls | HemOncToday
hemonctoday.com — “The American Academy of Pediatrics Committee on Infectious Diseases issued an updated policy statement on human papillomavirus vaccination that” View full resource at hemonctoday.com
Most Recently Shared on March 19, 2012 at 12:04 pm By:
The American Academy of Pediatrics Committee on Infectious Diseases recommends HPV vaccine for both boys and girls: http://t.co/QsBQaO48
Discovering the rewards of joining Twitter’s clinical medicine conversation | HemOncToday
hemonctoday.com — “As an oncology fellow, I had some interesting conversations with friends and colleagues about the use of patientphysician email in clin” View full resource at hemonctoday.com
Most Recently Shared on March 16, 2012 at 10:15 pm By:
Discovering the rewards of joining Twitter’s clinical medicine conversation http://t.co/Zkr2z4Cr via @WoodBD -->grt to have you involved!
Semuloparin linked to reduced thromboembolic events in patients receiving chemotherapy | HemOncToday
hemonctoday.com — “Patients receiving chemotherapy who were treated with semuloparin were more than 60% less likely to experience venous thromboembolism than patie” View full resource at hemonctoday.com
Most Recently Shared on March 15, 2012 at 10:00 pm By:
Semuloparin linked to reduced thromboembolic events in patients receiving chemotherapy: http://t.co/91nq1RYe
Increased mammography screening linked to reduced treatment, recurrence in women aged 40 to 49 years | HemOncToday
hemonctoday.com — “Increased mammography-detected breast cancer was associated with lower-stage disease detection resulting in reduced treatment and lower rates of” View full resource at hemonctoday.com
Most Recently Shared on March 14, 2012 at 7:46 pm By:
Increased mammography screening linked to reduced treatment, recurrence in women aged 40 to 49 years: http://t.co/JqvOlIZg
ODAC rejects expanded use for bone drug in men with prostate cancer | HemOncToday
hemonctoday.com — “The FDA’s Oncologic Drugs Advisory Committee rejected a request from Amgen to allow denosumab to be used as a preventive measure for men w” View full resource at hemonctoday.com
Most Recently Shared on February 9, 2012 at 1:11 pm By:
ODAC rejects expanded use for bone drug in men with prostate cancer: http://t.co/eFDclp28
FDA grants priority review for HER-2—positive breast cancer treatment | HemOncToday
hemonctoday.com — “FDA grants priority review for HER-2—positive breast cancer treatment | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on February 7, 2012 at 8:19 pm By:
FDA grants priority review for HER-2—positive breast cancer treatment: http://t.co/rr655isL
Packed red blood cells increased infection risk after cardiac surgery | HemOncToday
hemonctoday.com — “Patients with packed red blood cells had an increased risk for major infection after cardiac surgery, according to study results presented at” View full resource at hemonctoday.com
Most Recently Shared on February 3, 2012 at 3:58 pm By:
“...reducing packed red blood cell transfusions may significantly reduce incidence of major post-operative infections” http://t.co/NER4XlT0
FDA approves imatinib mesylate tablets for GIST | HemOncToday
hemonctoday.com — “The FDA today approved imatinib mesylate tablets for the adjuvant treatment of adult patients after complete gross resection of CD117-positive g” View full resource at hemonctoday.com
Most Recently Shared on February 1, 2012 at 3:58 pm By:
FDA approves imatinib mesylate tablets for GIST: http://t.co/T6fr3gKa
Monoclonal antibody detected early-stage pancreatic cancer marker | HemOncToday
hemonctoday.com — “Monoclonal antibody detected early-stage pancreatic cancer marker | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on January 31, 2012 at 1:02 pm By:
"The study shows tremendous promise that the serum can add significantly to our ability to diagnose pancreatic cancer" http://t.co/QJs1gp00
FDA approves first drug for metastatic basal cell carcinoma | HemOncToday
hemonctoday.com — “FDA approves first drug for metastatic basal cell carcinoma | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on January 30, 2012 at 9:07 pm By:
FDA approves vismodegib for the treatment of adults with basal cell carcinoma: http://t.co/Yl35XCgo
NO16968: Xelox improved 7-year OS in advanced colon cancer | HemOncToday
hemonctoday.com — “NO16968: Xelox improved 7-year OS in advanced colon cancer | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on January 23, 2012 at 8:16 pm By:
"The death rate due to colon cancer was 26% for 5-FU/leucovorin and 20% for Xelox...” http://t.co/h7nqx8XW

